ASND Ascendis Pharma A/S

113
+0.39  (+0%)
Previous Close 112.61
Open 111.12
Price To Book 7.33
Market Cap 5,394,580,111
Shares 47,739,647
Volume 364,737
Short Ratio
Av. Daily Volume 177,821
Stock charts supplied by TradingView

NewsSee all news

  1. Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

    – On track with 2020 corporate milestones –             – Top-line data from PaTH Forward phase 2 trial on track for mid-April – – Conference call today at 4:30 p.m. Eastern Time – COPENHAGEN, Denmark, April 01, 2020

  2. Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1

    COPENHAGEN, Denmark, March 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  3. Ascendis Pharma A/S Announces Upcoming Investor Presentation in February

    COPENHAGEN, Denmark, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  4. Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

    COPENHAGEN, Denmark, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will

  5. Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

    COPENHAGEN, Denmark, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

BLA filing due 2Q 2020.
TransCon hGH
Growth hormone deficiency in children
Phase 2 top-line data due mid-April 2020.
TransCon
Hypoparathyroidism
Phase 2 trial has been initiated.
TransCon CNP - ACcomplisH
Achondroplasia

Latest News

  1. Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

    – On track with 2020 corporate milestones –             – Top-line data from PaTH Forward phase 2 trial on track for mid-April – – Conference call today at 4:30 p.m. Eastern Time – COPENHAGEN, Denmark, April 01, 2020

  2. Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1

    COPENHAGEN, Denmark, March 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  3. Ascendis Pharma A/S Announces Upcoming Investor Presentation in February

    COPENHAGEN, Denmark, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  4. Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

    COPENHAGEN, Denmark, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will

  5. Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

    COPENHAGEN, Denmark, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  6. Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

    – Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon™ hGH in 2020 advance on track – – Expanded PaTH Forward Trial expedites enrollment of subjects previously

  7. Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

    - Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed targeted enrollment

  8. Ascendis Pharma A/S Announces Upcoming Investor Presentation in November

    COPENHAGEN, Denmark, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  9. Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019

    – A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor –                – 

  10. Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18

    COPENHAGEN, Denmark, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  11. Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

    COPENHAGEN, Denmark, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced

  12. Ascendis Pharma A/S Announces Upcoming Investor Presentation in October

    COPENHAGEN, Denmark, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

  13. Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

    – TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of achondroplasia on children

  14. Ascendis Pharma A/S Announces Three Investor Presentations in September

    COPENHAGEN, Denmark, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced